WO2007103787A3 - Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation - Google Patents

Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation Download PDF

Info

Publication number
WO2007103787A3
WO2007103787A3 PCT/US2007/063177 US2007063177W WO2007103787A3 WO 2007103787 A3 WO2007103787 A3 WO 2007103787A3 US 2007063177 W US2007063177 W US 2007063177W WO 2007103787 A3 WO2007103787 A3 WO 2007103787A3
Authority
WO
WIPO (PCT)
Prior art keywords
tendon
tendinopathy
molecules
inhibition
contribute
Prior art date
Application number
PCT/US2007/063177
Other languages
French (fr)
Other versions
WO2007103787A2 (en
Inventor
Joanne M Archambault
Scott Jelinsky
Original Assignee
Wyeth Corp
Joanne M Archambault
Scott Jelinsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Joanne M Archambault, Scott Jelinsky filed Critical Wyeth Corp
Priority to BRPI0708527-3A priority Critical patent/BRPI0708527A2/en
Priority to CA002644708A priority patent/CA2644708A1/en
Priority to EP07757795A priority patent/EP1991276A2/en
Priority to JP2008558476A priority patent/JP2009533321A/en
Priority to MX2008011138A priority patent/MX2008011138A/en
Priority to AU2007223383A priority patent/AU2007223383A1/en
Publication of WO2007103787A2 publication Critical patent/WO2007103787A2/en
Publication of WO2007103787A3 publication Critical patent/WO2007103787A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides methods for treating tendinopathy. The disorders treated or prevented include, for example tendinitis, tendonitis, tendinosis, paratendinitis, tenocynovitis, tendon overuse injury and trauma, peritendinitis, paratenonitis, or other tendon degenerative disorders. The disclosed therapeutic methods include administering to a patient an inhibitor of molecules involved in cartilage or fibrocartilage formation in tendinopathic tendon in an amount effective to treat or prevent a tendon degenerative disorder, slow tendon deterioration, restore tendon healthy structure, stimulate tendon regeneration, and/or maintain tendon mass and/or quality.
PCT/US2007/063177 2006-03-03 2007-03-02 Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation WO2007103787A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0708527-3A BRPI0708527A2 (en) 2006-03-03 2007-03-02 treatment of tendinopathy by inhibiting molecules that contribute to the formation of cartilage
CA002644708A CA2644708A1 (en) 2006-03-03 2007-03-02 Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation
EP07757795A EP1991276A2 (en) 2006-03-03 2007-03-02 Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation
JP2008558476A JP2009533321A (en) 2006-03-03 2007-03-02 Treatment of tendinopathy by inhibiting molecules that contribute to cartilage formation
MX2008011138A MX2008011138A (en) 2006-03-03 2007-03-02 Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation.
AU2007223383A AU2007223383A1 (en) 2006-03-03 2007-03-02 Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77916506P 2006-03-03 2006-03-03
US60/779,165 2006-03-03

Publications (2)

Publication Number Publication Date
WO2007103787A2 WO2007103787A2 (en) 2007-09-13
WO2007103787A3 true WO2007103787A3 (en) 2007-11-15

Family

ID=38190750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/063177 WO2007103787A2 (en) 2006-03-03 2007-03-02 Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation

Country Status (8)

Country Link
EP (1) EP1991276A2 (en)
JP (1) JP2009533321A (en)
CN (1) CN101432026A (en)
AU (1) AU2007223383A1 (en)
BR (1) BRPI0708527A2 (en)
CA (1) CA2644708A1 (en)
MX (1) MX2008011138A (en)
WO (1) WO2007103787A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2217249A4 (en) * 2007-11-06 2011-10-12 Benaroya Res Inst Inhibition of versican with sirna and other molecules
EP3169334B1 (en) 2014-07-16 2021-04-28 Ethris GmbH Rna for use in the treatment of ligament or tendon lesions
EP3604531A4 (en) * 2017-03-31 2020-12-23 Aichi Medical University Antisense nucleic acid for inhibiting biosynthesis of chondroitin sulfate
RU2757081C1 (en) * 2020-09-21 2021-10-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) Method for stimulating reparative regeneration in tendopathies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARCHAMBAULT J M ET AL: "Rat supraspinatus tendon expresses cartilage markers with overuse", JOURNAL OF ORTHOPAEDIC RESEARCH, THE JOURNAL OF BONE AND JOINT SURGERY, INC.,, US, vol. 25, no. 2, 22 February 2007 (2007-02-22), pages 617 - 624, XP009086178, ISSN: 0736-0266 *
CORPS A N ET AL: "Increased expression of aggrecan and biglycan mRNA in Achilles tendinopathy", RHEUMATOLOGY (OXFORD), vol. 45, no. 3, March 2006 (2006-03-01), pages 291 - 294, XP002442132, ISSN: 1462-0324 *
SUGAHARA K ET AL: "Heparin and heparan sulfate biosynthesis", IUBMB LIFE, TAYLOR AND FRANCIS, LONDON,, GB, vol. 54, no. 4, 2002, pages 163 - 175, XP002977758, ISSN: 1521-6543 *
VOGEL K G: "What happens when tendons bend and twist? Proteoglycans", JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, vol. 4, no. 2, June 2004 (2004-06-01), pages 202 - 203, XP009086495, ISSN: 1108-7161 *
WILSON JOHN J ET AL: "Common overuse tendon problems: A review and recommendations for treatment.", AMERICAN FAMILY PHYSICIAN 1 SEP 2005, vol. 72, no. 5, 1 September 2005 (2005-09-01), pages 811 - 818, XP009086334, ISSN: 0002-838X *

Also Published As

Publication number Publication date
MX2008011138A (en) 2008-09-08
AU2007223383A1 (en) 2007-09-13
BRPI0708527A2 (en) 2011-05-31
CA2644708A1 (en) 2007-09-13
CN101432026A (en) 2009-05-13
WO2007103787A2 (en) 2007-09-13
EP1991276A2 (en) 2008-11-19
JP2009533321A (en) 2009-09-17

Similar Documents

Publication Publication Date Title
MX2010006519A (en) Method for treating bone fracture with anti-sclerostin antibodies.
EA200100873A1 (en) SOLID FORM OF CELLO-COXYB THAT HAS IMPROVED BIO ACCESSIBILITY
MY188457A (en) Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
EA201000603A1 (en) APPLICATION OF ANTIBODIES TO TRKB FOR THE TREATMENT OF RESPIRATORY DISTURBANCES
WO2007100675A3 (en) Collagenase for treating cellulite
WO2010151671A3 (en) Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
SE9803710D0 (en) Use of certain drugs for treating nerve root injury
WO2008011083A3 (en) Compounds for enhancing arginase activity and methods of use thereof
WO2007143231A3 (en) Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
WO2004108157A8 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
WO2011084455A3 (en) Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
MX343397B (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof.
DK1970059T3 (en) Calcium dobesilate drug for the treatment and prophylaxis of tendon disorders
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
BRPI0512161A (en) methods for treating and preventing a paroxysmal disorder in an adult or young animal, to increase the limit of attacks on an animal's brain or neural tissue, to treat and prevent pain in an animal, and to reduce epileptic outbreak in brain cells; pharmaceutical
WO2006078870A3 (en) Methods for treating adhesive capsulitis
WO2007011702A3 (en) Use of egfr inhibitors to prevent or treat obesity
WO2007103787A3 (en) Treatment of tendinopathy by inhibition of molecules that contribute to cartilage formation
ATE525084T1 (en) USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR THE TREATMENT OF PAIN RESULTING FROM THERAPEUTIC TREATMENTS FOR THE AIDS VIRUS
WO2004016256A3 (en) AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
WO2005077082A3 (en) INHIBITING CAV3 ISOFORMS AND THE δ25B SPLICE VARIENTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
WO2013039956A3 (en) Compositions and methods for treating mood disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007757795

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/011138

Country of ref document: MX

Ref document number: 2644708

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007223383

Country of ref document: AU

Ref document number: 2008558476

Country of ref document: JP

Ref document number: 3609/KOLNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007223383

Country of ref document: AU

Date of ref document: 20070302

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200780015676.6

Country of ref document: CN

ENP Entry into the national phase

Ref document number: PI0708527

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080903